- Home
- Publications
- Publication Search
- Publication Details
Title
Trial Watch: Lenalidomide-based immunochemotherapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 2, Issue 11, Pages e26494
Publisher
Informa UK Limited
Online
2013-12-07
DOI
10.4161/onci.26494
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pomalidomide approved for multiple myeloma
- (2013) K. Traynor AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide
- (2013) Vaishali Sanchorawala et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
- (2013) F. Hitz et al. ANNALS OF HEMATOLOGY
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
- (2013) A. Rossi et al. BLOOD
- Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment
- (2013) A. Schulz et al. BLOOD
- High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
- (2013) Daniel Heintel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial
- (2013) Jeffrey Infante et al. CANCER BIOLOGY & THERAPY
- Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice
- (2013) K. M. Lee et al. DIABETES
- A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
- (2013) Franck Morschhauser et al. EUROPEAN JOURNAL OF CANCER
- Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels
- (2013) Alexandra J. Greenberg et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Pomalidomide in the treatment of relapsed multiple myeloma
- (2013) Peter A Forsberg et al. Future Oncology
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Enhanced cross-priming of naive CD8+T cells by dendritic cells treated by the IMiDs®immunomodulatory compounds lenalidomide and pomalidomide
- (2013) Jake Y. Henry et al. IMMUNOLOGY
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer
- (2013) Prasanth Ganesan et al. INVESTIGATIONAL NEW DRUGS
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Decoding cell death signals in liver inflammation
- (2013) Catherine Brenner et al. JOURNAL OF HEPATOLOGY
- Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas
- (2013) I Sakamaki et al. LEUKEMIA
- Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
- (2013) M Le Garff-Tavernier et al. LEUKEMIA
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
- (2013) M Wang et al. LEUKEMIA
- Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro
- (2013) C. Mahony et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The two faces of regulatory T cells in cancer
- (2013) Nichole R Blatner et al. OncoImmunology
- Myeloid derived suppressor cells
- (2013) Todd J. Waldron et al. OncoImmunology
- Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
- (2013) Weiyi Peng et al. OncoImmunology
- Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors
- (2013) Nadine M. Lerret et al. OncoImmunology
- Myeloid-derived suppressor cells and the efficacy of CD8+T-cell immunotherapy
- (2013) Alexander M. Lesokhin et al. OncoImmunology
- High-density lipoproteins delivering interleukin-15
- (2013) Maria C. Ochoa et al. OncoImmunology
- Targeting two co-operating cytokines efficiently shapes immune responses
- (2013) Andreas A. Hombach et al. OncoImmunology
- Toward the next generation of NK cell-based adoptive cancer immunotherapy
- (2013) Jing Ni et al. OncoImmunology
- Trial Watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Laura Senovilla et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2013) Laurie Menger et al. OncoImmunology
- Retinoids in Pediatric Onco-Hematology: the Model of Acute Promyelocytic Leukemia and Neuroblastoma
- (2012) Riccardo Masetti et al. ADVANCES IN THERAPY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4
- (2012) Kwang Min Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
- (2012) M. A. Sekeres et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
- (2012) P. G. Richardson et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
- (2012) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
- (2012) Heather E. Eve et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells
- (2012) Jaehyup Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase II Study of Lenalidomide Alone in Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes With Chromosome 5 Abnormalities
- (2012) Yiming Chen et al. Clinical Lymphoma Myeloma & Leukemia
- Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules
- (2012) Marina Bolzoni et al. EXPERIMENTAL HEMATOLOGY
- Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
- (2012) Christine Wolschke et al. EXPERIMENTAL HEMATOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2012) Xavier C. Badoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma
- (2012) J R Berenson et al. LEUKEMIA
- Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients
- (2012) P Falco et al. LEUKEMIA
- A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
- (2012) G Ramsingh et al. LEUKEMIA
- Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
- (2012) Adrian Alegre et al. LEUKEMIA & LYMPHOMA
- Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial
- (2012) Dennis A. Revicki et al. LEUKEMIA RESEARCH
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Mitochondria: master regulators of danger signalling
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia
- (2012) E Lainey et al. ONCOGENE
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
- (2012) Lorenzo Galluzzi et al. Cell Reports
- Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
- (2012) Andy Hsu et al. OncoImmunology
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Targeting the right regulatory T-cell population for tumor immunotherapy
- (2012) Vivian L. Weiss et al. OncoImmunology
- Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
- (2012) Ravi A Madan et al. OncoImmunology
- CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
- (2012) Rebecca Waitz et al. OncoImmunology
- Targeting the tumor mutanome for personalized vaccination therapy
- (2012) Sebastian Kreiter et al. OncoImmunology
- DNA vaccination against oncoantigens
- (2012) Manuela Iezzi et al. OncoImmunology
- Anticancer activity of cardiac glycosides
- (2012) Oliver Kepp et al. OncoImmunology
- Trial Watch: Monoclonal antibodies in cancer therapy
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial Watch
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch
- (2012) Laura Senovilla et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
- (2012) Erika Vacchelli et al. OncoImmunology
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
- (2012) Steffen Walter et al. OncoImmunology
- Improving the outcome of adoptive cell transfer by targeting tumor escape
- (2012) Karen M. Kaluza et al. OncoImmunology
- Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial
- (2011) Shaji K. Kumar et al. AMERICAN JOURNAL OF HEMATOLOGY
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Functional modulation of AMP-activated protein kinase by cereblon
- (2011) Kwang Min Lee et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- IMiD immunomodulatory compounds block C/EBP translation through eIF4E down-regulation resulting in inhibition of MM
- (2011) S. Li et al. BLOOD
- A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
- (2011) M. A. Sekeres et al. BLOOD
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
- (2011) T. A. Fehniger et al. BLOOD
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
- (2011) X. C. Badoux et al. BLOOD
- Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
- (2011) E. Kneppers et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
- (2011) Meaghan L. Khan et al. BRITISH JOURNAL OF HAEMATOLOGY
- The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
- (2011) Myron S. Czuczman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
- (2011) Antonia Lopez-Girona et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia
- (2011) Bang-Ning Lee et al. CANCER
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
- (2011) Oliver Kepp et al. CANCER AND METASTASIS REVIEWS
- Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia
- (2011) Sylvain Thépot et al. CELL CYCLE
- Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
- (2011) L Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
- (2011) Pier Luigi Zinzani et al. Clinical Lymphoma Myeloma & Leukemia
- Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
- (2011) F. Zaja et al. HAEMATOLOGICA
- Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
- (2011) L. Mollgard et al. HAEMATOLOGICA
- A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma
- (2011) Jori S. Carter et al. International Journal of Clinical Oncology
- Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein
- (2011) Craig C. Hofmeister et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
- (2011) G S Nowakowski et al. LEUKEMIA
- Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
- (2011) D A Pollyea et al. LEUKEMIA
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
- (2011) Clemens-Martin Wendtner et al. LEUKEMIA & LYMPHOMA
- Lenalidomide in del 5q MDS: Responses and side effects revisited
- (2011) Ramon V. Tiu et al. LEUKEMIA RESEARCH
- Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
- (2010) Mikkael A. Sekeres et al. AMERICAN JOURNAL OF HEMATOLOGY
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
- (2010) T. A. Fehniger et al. BLOOD
- Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
- (2010) J. A. Zonder et al. BLOOD
- The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
- (2010) A. K. Hsu et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Lenalidomide mode of action: linking bench and clinical findings
- (2010) Faith Davies et al. BLOOD REVIEWS
- Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma
- (2010) Greg Dueck et al. CANCER
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
- (2010) P. Mathew et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study
- (2010) D. Keizman et al. CLINICAL CANCER RESEARCH
- Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
- (2010) A. K. Gandhi et al. CURRENT CANCER DRUG TARGETS
- Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective
- (2010) Robert Bwire et al. Expert Opinion On Drug Safety
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
- (2010) J.-L. Harousseau et al. HAEMATOLOGICA
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
- (2010) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
- (2010) William Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018
- (2010) Katherine E. Warren et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
- (2010) Stacey L. Berg et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
- (2010) Christine I. Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
- (2010) S K Kumar et al. LEUKEMIA
- A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
- (2010) J R Brown et al. LEUKEMIA
- Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
- (2010) A Palumbo et al. LEUKEMIA
- Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
- (2010) Taimur Sher et al. LEUKEMIA & LYMPHOMA
- Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
- (2010) Zhengzi Qian et al. LEUKEMIA RESEARCH
- Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy
- (2010) Wen-Jen Hwu et al. MELANOMA RESEARCH
- Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
- (2010) Stephanie Markovina et al. Molecular Cancer
- Molecular mechanisms of necroptosis: an ordered cellular explosion
- (2010) Peter Vandenabeele et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
- (2009) Liang Zhang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies
- (2009) Dan Grandér et al. Autophagy
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
- (2009) D. Chauhan et al. BLOOD
- Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
- (2009) S. Knop et al. BLOOD
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
- (2009) P. Richardson et al. BLOOD
- Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases
- (2009) Y. Xu et al. BLOOD
- Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
- (2009) R. Lapalombella et al. BLOOD
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
- (2009) Boris Böll et al. BRITISH JOURNAL OF HAEMATOLOGY
- Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma
- (2009) John Glaspy et al. CANCER
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
- (2009) L. Escoubet-Lozach et al. CANCER RESEARCH
- Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
- (2009) Edward A. Stadtmauer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
- (2009) G. Aue et al. HAEMATOLOGICA
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
- (2009) William L. Dahut et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanism of action of lenalidomide in hematological malignancies
- (2009) Venumadhav Kotla et al. Journal of Hematology & Oncology
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia
- (2009) K Giannopoulos et al. LEUKEMIA
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13
- (2008) T. A. Fehniger et al. BLOOD
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
- (2008) A. Ferrajoli et al. BLOOD
- TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype
- (2008) R. C. A. Sainson et al. BLOOD
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia
- (2008) S. P. Treon et al. CLINICAL CANCER RESEARCH
- CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet
- (2008) Weiming Xu et al. CLINICAL IMMUNOLOGY
- RevAssist®
- (2008) Carmen P Castaneda et al. DRUG SAFETY
- A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2008) Jan Drappatz et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors
- (2008) Sharon L. Sanborn et al. INVESTIGATIONAL NEW DRUGS
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
- (2008) Leslie A. Andritsos et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
- (2008) I Breitkreutz et al. LEUKEMIA
- Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells
- (2008) M C Minnema et al. LEUKEMIA
- Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy
- (2008) M. Hazarika et al. ONCOLOGIST
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started